吉西他滨联合大剂量顺铂治疗晚期非小细胞肺癌

Clinical observation of combined chemotherapy of gemcitabine and HD-DDP for advanced non-small-cell Lung cancer.

目的观察吉西他滨(Gemcitabine GEM)联合大剂量顺铂(HD-DDP)方案治疗晚期非小细胞肺癌(ANSCLC)的近期疗效及其不良反应.方法经病理组织学或细胞学证实的26例晚期非小细胞肺癌用吉西他滨1000mg/m2静脉滴注,第1,8,15天,顺铂80～100mg/m2静脉滴注,第1天,4周为1周期.所有病人至少接受2周期治疗.结果可评价疗效26例,总有效率46.2%,初治病例14例,有效率57.1%.复治病例12例,有效率33.3%.主要毒副作用是骨髓抑制,恶心呕吐,其他毒性反应均轻微可耐受.结论吉西他滨联合大剂量顺铂治疗晚期非小细胞肺癌具有较好疗效,毒性可耐受,是治疗晚期非小细胞肺癌较理想方案之一.

Objective To evaluate the efficacy and to xi city of Gemcitabine and HD-DDP for advanced non-small-cell lung cancer. Methods Twenty six patients with ANSCLC diagnosed by pathology or cytology were enrolled in the study.The patients received Gemcitabine 1000mg/ m 2 on d1,8,15 and HD-DDP 80-100mg/ m2 on d1 of 4 weeks regimen. All patients received at least two cycles of the treatment. Results Tw enty six of all the cases could be evaluated.The total response rate (RR) was 4 6.2%,The RR of 14 the first treatment patients was 57.1%.The RR of 12 recurrent patients were 33.3%.The major side effects were neutropenia,nausea vomiting,the other toxicity were mild and tolerable. Conclusion The c ombination of Gemcitabine and HD-DDP is an effective and tolerable regimen in th e treatment of ANSCLC.It could be considered as one of the standard therapies.